Effect of the ET B Receptor Agonist,IRL-1620,on Paclitaxel Plasma Pharmacokinetics of Breast Tumor Rats

Abstract

Endothelin (ET)-B receptors are expressed in human breast carcinoma. We previously demonstrated that intravenous administration of the ET_B receptor agonist, IRL-1620, to tumor-bearing rats, increased blood perfusion and enhanced delivery of paclitaxel to breast tumor tissue. The present study was conducted to determine whether IRL-1620 alters the pharmacokinetics of paclitaxel. Breast tumor–bearing rats were given 0.3 ml/kg saline or 3 nmol/kg IRL-1620 by intravenous (iv) administration. Fifteen minutes after saline or IRL-1620, 40 μCi/rat ³H-Paclitaxel was administered iv and serial plasma samples were collected until 24 hrs. ³H-Paclitaxel radioactivity in the plasma samples was measured by liquid scintillation counting. Data were fit to a three-compartment model and pharmacokinetic parameters were generated using WinNonlin software. IRL-1620 did not produce any change in the plasma paclitaxel pharmacokinetics of tumor-bearing rats. The AUC_0–∞ (9.43 ± 3.18 μg-hr/ml), clearance (0.69 ± 0.17 l/hr/kg), volume of distribution (10.31 ± 4.54 l/kg), and half-life (1.0 ± 0.32 hrs) of paclitaxel were similar between rats treated with saline or IRL-1620. In conclusion, the ET_B receptor agonist, IRL-1620, does not alter paclitaxel plasma pharmacokinetics and, therefore, could be used to augment the delivery of paclitaxel to the tumor tissue.

Get full access to this article

View all access options for this article.

References

Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2:16, 2004.

Bagnato A, Natali PG. Targeting endothelin axis in cancer. Cancer Treat Res 119:293–314, 2004.

Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, Greb RR, Bocker W, Kiesel L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9:4125–4131, 2003.

Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Greb RR, Bocker W, Kiesel L. Endothelin-1, endothelin-A- and endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncol Rep 11:791–796, 2004.

Rai A, Gulati A. Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor. Cancer Chemother Pharmacol 51:21–28, 2003.

Takai M, Umemura I, Yamasaki K, Watakabe T, Fujitani Y, Oda K, Urade Y, Inui T, Yamamura T, Okada T. A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8–21), IRL-1620, for the ETB receptor. Biochem Biophys Res Commun 184:953–959, 1992.

Rajeshkumar NV, Rai A, Gulati A. Endothelin B receptor agonist, IRL-1620, enhances the antitumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 94:237–247, 2005.

Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv 17:283–304, 1993.

Mehta RG. Experimental basis for the prevention of breast cancer. Eur J Cancer 36:1275–1282, 2000.

10.

Lhuillery C, Bougnoux P, Groscolas R, Durand G. Time-course study of adipose tissue fatty acid composition during mammary tumor growth in rats with controlled fat intake. Nutr Cancer 24:299–309, 1995.

11.

Buehler PW, Haney CR, Gulati A, Ma L, Hsia CJ. Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms. Free Radic Biol Med 37:124–135, 2004.

12.

Rubin SA, Levin ER. Clinical review 53: the endocrinology of vasoactive peptides: synthesis to function. J Clin Endocrinol Metab 78:6–10, 1994.

13.

Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436, 2004.

14.

Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 5:13–17, 2004.

15.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342, 2004.

16.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027, 2005.

17.

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62, 2005.

18.

Gulati A, Rai A, Rajeshkumar NV. ET B receptor agonist, IRL-1620, enhances the efficacy of paclitaxel in reducing breast tumor volumes in rats (abstract 1443). In: Program of the 96th AACR annual meeting, Anaheim, CA; p338, 2005.

19.

Rajeshkumar NV, Rai A, Green A, Gionetti G, Das Gupta TK, Gulati A. Endothelin B receptor agonist, IRL-1620, increases blood perfusion and enhances paclitaxel delivery to tumor (abstract 5741). In: Program of the 96th AACR annual meeting, Anaheim, CA; p1349, 2005.